Related Experiment Video
Updated: Jun 7, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
LncRNA MEG3 aggravates acute pulmonary embolism-induced pulmonary arterial hypertension by regulating
Jianfeng Song1, Jinyan Shao1, Shuili Yu1
1Emergency Department, Minhang Hospital, Fudan University, 170 Xinsong Road, Minhang District, Shanghai 201199, PR China.
Abstract:
Acute pulmonary embolism (APE)-induced pulmonary artery hypertension (PAH) is a fatal disease. The miR-34-3p/DUSP1 has inhibitory effects on the thickening of the pulmonary arterial walls in APE rats and the proliferation of platelet-derived growth factor-BB (PDGF-BB)-induced human pulmonary arterial smooth muscle cells (hPASMCs). Herein, the lncRNAs regulating the miR-34a-3p/DUSP1 axis in APE and PAH are further explored in vitro and in vivo. MEG3 targeted miR-34a-3p. MEG3 overexpression potentiated the effects of PDGF-BB treatment on promoting the viability and proliferation of hPASMCs, as well as the mPAP level in APE rats. Also, overexpressed MEG3 strengthened PDGF-BB-induced upregulation of MEG3, NOR-1, PCNA and DUSP1, as well as downregulation of miR-34a-3p in hPASMCs and APE rats. However, shMEG3 generated opposite effects. MiR-34a-3p mimic reversed the effect of MEG3 overexpression, and DUSP1 overexpression neutralized the effect of MEG3 downregulation on PDGF-BB-induced hPASMCs and APE rats.MEG3 aggravates APE-induced PAH by regulating miR-34a-3p/DUSP1 axis, holding a great promise as a novel biomarker for PAH treatment.
Insights
Long non-coding RNA MEG3 aggravates acute pulmonary embolism-induced pulmonary hypertension by regulating the miR-34a-3p/DUSP1 pathway. This finding offers a potential new biomarker for pulmonary hypertension treatment.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pulmonary Medicine
Background:
- Acute pulmonary embolism (APE)-induced pulmonary artery hypertension (PAH) is a critical condition.
- The miR-34a-3p/DUSP1 pathway plays a role in regulating pulmonary arterial wall thickening and smooth muscle cell proliferation.
Purpose of the Study:
- To investigate the role of long non-coding RNAs (lncRNAs) in regulating the miR-34a-3p/DUSP1 axis in APE and PAH.
- To explore MEG3 as a potential regulator in this pathway.
Main Methods:
- In vitro studies using platelet-derived growth factor-BB (PDGF-BB)-induced human pulmonary arterial smooth muscle cells (hPASMCs).
- In vivo studies using a rat model of APE.
- Manipulation of MEG3 and miR-34a-3p levels using overexpression and knockdown techniques.
- Assessment of cell viability, proliferation, and mean pulmonary arterial pressure (mPAP).
Main Results:
- MEG3 was found to target miR-34a-3p.
- MEG3 overexpression exacerbated PDGF-BB-induced hPASMC proliferation and increased mPAP in APE rats.
- MEG3 influenced the expression of key genes including NOR-1, PCNA, and DUSP1, while downregulating miR-34a-3p.
- Inhibition of MEG3 (shMEG3) produced opposite effects.
- MiR-34a-3p mimic reversed MEG3 overexpression effects, and DUSP1 overexpression counteracted MEG3 downregulation effects.
Conclusions:
- MEG3 aggravates APE-induced PAH by modulating the miR-34a-3p/DUSP1 axis.
- MEG3 presents potential as a novel biomarker for PAH treatment.
Related Concept Videos
MicroRNAs
lncRNA - Long Non-coding RNAs
Abnormal Proliferation
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

